Skip to Main Content

SAN DIEGO — I didn’t expect so much optimism about CAR-T cancer therapies at ASH, the annual American Society of Hematology meeting.

We’re coming off a rough couple of months in the field; seven patients have died across three clinical trials of Juno Therapeutics’s CAR-T treatments. And we’ve heard a lot about the often-toxic side effects, starting with the cytokine storms that can overwhelm the immune system.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.